Canakinumab

Canakinumab
Ribbon diagram of canakinumab (blue) bound to IL-1β (yellow) from PDB entry 5bvp[1]
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL-1β
Clinical data
Trade namesIlaris
Other namesACZ885, ACZ-885
AHFS/Drugs.comMonograph
MedlinePlusa622024
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Intravenous, subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only[2]
  • EU: Rx-only[3]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6452H9958N1722O2010S42
Molar mass145157.20 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares.[4][5][6] It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.[7]

Common side effects include infections (colds and upper respiratory tract infections), abdominal pain and injection-site reactions.[2][3][4]

  1. ^ Rondeau JM, Ramage P, Zurini M, Gram H (2015). "The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β". mAbs. 7 (6): 1151–1160. doi:10.1080/19420862.2015.1081323. PMC 4966334. PMID 26284424.
  2. ^ a b Cite error: The named reference Ilaris FDA label was invoked but never defined (see the help page).
  3. ^ a b Cite error: The named reference Ilaris EPAR was invoked but never defined (see the help page).
  4. ^ a b "FDA Approves First Treatment for Adult Onset Still's Disease, a Severe and Rare Disease". U.S. Food and Drug Administration (FDA) (Press release). 16 June 2020. Retrieved 16 June 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ Dhimolea E (2010). "Canakinumab". mAbs. 2 (1): 3–13. doi:10.4161/mabs.2.1.10328. PMC 2828573. PMID 20065636.
  6. ^ "FDA Approves Canakinumab for Gout Flares". Medscape. Retrieved 1 September 2023.
  7. ^ Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. (June 2009). "Use of canakinumab in the cryopyrin-associated periodic syndrome". The New England Journal of Medicine. 360 (23): 2416–2425. doi:10.1056/NEJMoa0810787. PMID 19494217.